文献速递胸部肿瘤

等位基因频率校正的血液肿瘤突变负荷预测NSCLC免疫治疗总生存

Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors.
PubMed 文献 · J Thorac Oncol · 2019-12-12

研究在POPLAR、OAK和NCC三个独立NSCLC免疫治疗队列中开发并验证了一种新的血液肿瘤突变负荷算法。未校正的bTMB-high与总生存无关,而低等位基因频率bTMB(LAF-bTMB)高与免疫治疗后更好的OS、PFS和ORR相关,并在NCC队列中进一步验证。

要点

  • 未校正bTMB-high与免疫治疗后OS无关,因其与循环肿瘤DNA量相关。
  • LAF-bTMB(AF≤5%的突变计数)高与免疫治疗后OS、PFS和ORR改善相关。
  • LAF-bTMB算法在POPLAR和OAK中开发验证,并在NCC队列中进一步验证。

核心结论

  • 开发并验证了一种新的LAF-bTMB算法,可作为NSCLC患者抗PD-(L)1治疗后OS、PFS和ORR的可行预测指标,尚需前瞻性验证。

研究设计与样本

  • 研究使用三个独立的NSCLC免疫治疗患者队列:POPLAR(N=211)和OAK(N=462)用于开发算法,NCC队列(N=64)用于验证。

主要发现

  • 在POPLAR和OAK队列中,无论 cutoff 点如何,bTMB-H与免疫治疗后OS无关(p>0.05),因其与循环肿瘤DNA量相关。
  • 在POPLAR和OAK队列中,HAF-bTMB与循环肿瘤DNA量强相关(Pearson r=0.65),而LAF-bTMB不相关(Pearson r=0.09)。
  • LAF-bTMB-H与免疫治疗后有利的OS相关(HR=0.70,95%CI:0.52-0.95,p=0.02),PFS相关(HR=0.62,95%CI:0.47-0.80,p<0.001),ORR相关(p<0.001),但与化疗无关,cutoff点为12(在POPLAR中训练,OAK中验证)。
  • 在NCC队列中,LAF-bTMB-H与OS相关(HR=0.20,95%CI:0.05-0.84,p=0.02),PFS相关(HR=0.30,95%CI:0.13-0.70,p=0.003),ORR相关(p=0.001)。

关键数值与推荐

  • LAF-bTMB定义为等位基因频率(AF)≤5%的突变计数,cutoff点为12。

临床怎么用

  • LAF-bTMB算法可用于筛选可能从抗PD-(L)1治疗中获益的NSCLC患者,但需前瞻性验证。

局限性

  • LAF-bTMB算法需要前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Blood-based tumor mutational burden (bTMB) has been studied to identify patients with NSCLC who would benefit from anti-programmed cell death protein 1 (anti-PD-1) or anti-programmed death ligand 1 (anti-PD-L1) therapies. However, it failed to predict overall survival (OS) benefits, which warrants further exploration. METHODS: Three independent cohorts of patients with NSCLC treated with immunotherapy were used in this study. A new bTMB algorithm was first developed in the two independent cohorts (POPLAR, N = 211, and OAK, N = 462) and further validated in the third National Cancer Center (NCC) cohort (N = 64). RESULTS: bTMB-H (bTMB ≥ cutoff point) was not associated with favorable OS after immunotherapy regardless of the cutoff points in either the POPLAR and OAK or the NCC cohorts (p > 0.05) owing to its correlation with the amount of circulating tumor DNA, which was associated with poor OS. In the POPLAR and OAK cohorts, with allele frequency (AF) adjustment, a high AF bTMB (HAF-bTMB, mutation counts with an AF > 5%) was strongly correlated with the amount of circulating tumor DNA (Pearson r = 0.65), whereas a low AF bTMB (LAF-bTMB, mutation counts with an AF ≤ 5%) was not (Pearson r = 0.09). LAF-bTMB-H was associated with favorable OS (hazard ratio [HR] = 0.70, 95% confidence interval [CI]: 0.52-0.95, p = 0.02), progression-free survival (PFS; HR = 0.62, 95% CI: 0.47-0.80, p < 0.001), and objective response rate (ORR) (p < 0.001) after immunotherapy but not chemotherapy, with a cutoff point of 12 trained in the POPLAR cohort and validated in the OAK cohort. The LAF-bTMB algorithm was further validated in the NCC cohort in which LAF-bTMB-H was associated with OS (HR = 0.20, 95% CI: 0.05-0.84, p = 0.02), PFS (HR = 0.30, 95% CI: 0.13-0.70, p = 0.003), and ORR (p = 0.001). CONCLUSIONS: We developed and validated a new LAF-bTMB algorithm as a feasible predictor of OS, PFS, and ORR after anti-PD-(L)1 therapies in patients with NSCLC, which needs to be prospectively validated.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Wang Z, Duan J, Wang G, et al. Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors. J Thorac Oncol. 2019. PMID: 31843683. doi:10.1016/j.jtho.2019.12.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。